Peptide·plain sequence-like

ATLPC0026740

YGGFM

Routes

Compare in workbench Download release API JSON

Length
5 aa
Monoisotopic mass
573.2 Da
Net charge @ pH 7.4
0.00
Isoelectric point
6.10
GRAVY
0.520

Coveragecounts only · not riskATLPC0026740

Measurements
24
Endpoints
3
Domains
3/5
Products
—

2 stability measurements
12 clearance measurements
No immunogenicity context
2 liability motifs

Jump to domain

Open the matching evidence section below

All evidence index · 24

Exposure / Absorption

No evidence

Distribution / Barrier

10 measurements

Metabolic & Proteolytic Stability

2 measurements

Excretion / Persistence

12 measurements

Toxicity / Safety

No evidence

Sequence & molecular identity

1 forms

Reviewed sequence, peptidoform forms, chemical representation, 3D references, and covalent topology used to interpret this peptide identity.

Sequence & peptidoform

Identity summaryCanonical sequence only

Identity status: Canonical sequence only
Residues: 5
Peptidoform features: 0
Documented molecular forms: 1
Representations: 2

Documented molecular forms1 form linked to this peptide identity

Form	Topology	Modifications	Connections	Representations	Measurements
ATLPF0029076	—	—	—	Notation only	14

Residue view

Residue display

5 residues

Y1G2G3F4M5

Secondary structureα-helix (H)β-strand (E)coil (C)

Side-chain classNonpolarPolarBasic (+)Acidic (−)Modified

Soft tints mark standard side-chain classes for scanning. Primary emphasis is reserved for reported modifications, termini, secondary-structure tracks, and topology links.

Peptidoform features

Features are shown only when a reported notation or topology record supports them.

No terminal modification, residue-level marker, disulfide, staple, coordination, or other topology signal is currently available.

Structure & chemistry

Chemical representationsequence / HELM only

Representation class

How the current release can interpret this identity chemically.

plain sequence-like

Parent-residue sequence

Residue string used for positional interpretation when available.

YGGFM

HELM

Polymer notation for modified peptide representation when available.

Not available

SMILES

Chemical graph string used for atom-level 2D depiction when available.

Not available

No atom-level graph

A reviewed SMILES is required before a 2D molecular depiction can be shown. Sequence and HELM remain useful for identity interpretation, but they do not replace a chemical graph.

3D structure references1 reference

3D coordinates·Exact PDB matchexperimental

Exact PDB match·reference selected·length 5 aa·confidence experimental

Link	Method	Confidence	Match
Open	Experimental coordinate entry	experimental	5 aa

Covalent topology & modificationsnone

Exact topology not established

No reviewed form-level topology or residue-level connection annotation is attached to this peptide in the current release. This is not evidence that every molecular form is linear or unmodified.

Physicochemical profile

4 descriptors

Computed sequence-derived descriptors and any measured physicochemical evidence such as lipophilicity. Computed values are interpretation aids, not experimental ADMET measurements.

Core descriptors5 aa · pI 6.1 · GRAVY 0.52

Length: 5 aa
Monoisotopic mass: 573.23 Da
Average mass: 573.66 Da
Net charge at pH 7.4: 0.00
Estimated pI: 6.10
GRAVY: 0.520
KD-positive residues: 40.0%
Aromatic residues: 40.0%

Developability interpretation

Ionization context: pH 7.4 separated from pI
Hydrophobicity balance: Leans hydrophobic
Amphipathic moment (μH): 0.49
Computation boundary: Standard-sequence only

Charge & residue composition

pH charge context

Modeled net charge across common formulation and assay pH checkpoints.

pH 2

0.98

pH 5

0.04

pH 6

0.00

pH 7.4

-0.06

pH 9

-0.79

pH 12

-1.99

Residue-class composition

Grouped composition is often more interpretable than a long amino-acid list.

Hydrophobic aliphatic (A,V,I,L,M)

1 · 20.0%

Aromatic (F,W,Y)

2 · 40.0%

Conformational / sulfur (G,P,C)

2 · 40.0%

Top residues

G240.0%M120.0%F120.0%Y120.0%

Hydropathy & amphipathic windows

Hydropathy windows

Seven-residue sliding windows expose local patches hidden by whole-sequence GRAVY.

Most hydrophobic window

1-5

YGGFM

GRAVY 0.520

Most hydrophilic window

1-5

YGGFM

GRAVY 0.520

1 local hydropathy window scanned. A local patch is context for solubility, adsorption, and membrane interaction review, not a standalone endpoint.

Amphipathic-window scan

Top alpha-helix hydrophobic-moment windows across 12, 15, 18, and 21 residues.

Sequence is shorter than the local amphipathic-window sizes used here.

Sequence-liability cues

Sequence-liability notes

Motifs are review prompts for formulation or CMC interpretation; they are not degradation predictions.

Oxidation-sensitive residues

M · pos 5

Met, Trp, and Cys residues can merit formulation review for oxidation or covalent-state sensitivity.

Pro/Gly-rich sequence

P/G · pos 2, 3

High Pro/Gly content can affect local flexibility and secondary-structure propensity.

Method notes

Charge model: side-chain pKa D 3.9, E 4.1, C 8.5, Y 10.1, H 6.5, K 10.8, R 12.5 with EMBOSS termini. pI is estimated by binary search on modeled net charge. Hydropathy uses Kyte-Doolittle values; hydrophobic moment follows the Eisenberg alpha-helix vector-sum convention. When the basis is a parent-residue sequence, modified chemistry is intentionally not inferred.

Computed developability descriptors

Deterministic descriptors computed from the reviewed sequence or chemical structure (RDKit), each anchored to a literature method. These are computed estimates for developability interpretation — not experimental measurements — and are validated against independent reference implementations.

Sequence-derived

Computed from the standard parent-residue sequence; protein-origin metrics defined at any length.

Aliphatic index

0.00

Instability index

15.7

At or below 40 — predicted stable in vitro.

Boman index

-1.41 kcal/mol

Molar extinction coefficient (280 nm)

1,490 M⁻¹·cm⁻¹

A280 (1 g/L) ≈ 2.60

Structure-derived descriptors are not shown because this identity has no resolved chemical structure (SMILES). This is a known coverage gap for disulfide-rich and unresolved peptidoforms, not a computation error.

Distribution / Barrier

10 records

What is known about distribution, binding, permeability, or barrier crossing?

Evidence records

Complete canonical measurements and observations attached to this domain.

Endpoint scope

Formal ADMET endpoints represented for this peptide.

Matched-context in preview

Quantitative results that may be analysed only with scientifically compatible records.

Reported results in preview

Qualitative, narrative, or review-first results interpreted in their source context.

Endpoints in scopeBBB penetration

Loading 10 Distribution / Barrier records…

Barrier and permeability assay context

PAMPA, Caco-2, MDCK/RRCK, and BBB findings are assay/model contexts under Distribution / Barrier. They should not be read as interchangeable measurements.

PAMPA

artificial membrane

Caco-2

cell monolayer

MDCK

cell monolayer

RRCK

cell monolayer

BBB

barrier evidence

Metabolic & Proteolytic Stability

2 records

How stable is the peptide in biological matrices or protease systems?

Evidence records

Complete canonical measurements and observations attached to this domain.

Endpoint scope

Formal ADMET endpoints represented for this peptide.

Matched-context analysis

Quantitative results that may be analysed only with scientifically compatible records.

Reported-result review

Qualitative, narrative, or review-first results interpreted in their source context.

Endpoints in scopeSerum/plasma stability

Evidence interpretation

Result type, analysis use, and source-check status are kept separate so a numerical value is not mistaken for a universally comparable result.

Eligible for matched-context analysis

Quantitative results whose endpoint and context must still be matched before analysis.

Interpret as reported

Qualitative, narrative, or review-first findings preserved in source context.

Supporting context only

Reference, label, clinical, or supporting context for interpretation.

Review before analysis

Records whose present structure does not establish a safe analysis role.

Evidence by endpoint

Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.

Serum/plasma stability2 records · 2 matched-context · 0 as reported · 0 context only · 0 review required

#	Value	Analysis use	Assay / model	Result context	Reference
1	< 2 minutes < 120 seconds	Eligible when experimental context matches	RP-HPLC · monkey · Rhesus monkey plasma	Result: Upper-bound measurement · Molecular form: ATLPF0029076 · Dose/window: 1-20mM · Time: Blood collected 5-60 minutes after peptide infused · Proteases from rhesus monkey plasma · in vitro · Source: Primary reference linked	Reference
2	12.8 minutes 768 seconds	Eligible when experimental context matches	TLC (Thin-layer chromatography) · human · Human plasma	Result: Reported point value · Molecular form: ATLPF0029076 · Dose/window: 300pg (pooled platelet-poor plasma) · Human plasma proteases · in vitro · Source: Primary reference linked	Reference

Excretion / Persistence

12 records

What evidence describes clearance or persistence?

Evidence records

Complete canonical measurements and observations attached to this domain.

Endpoint scope

Formal ADMET endpoints represented for this peptide.

Matched-context analysis

Quantitative results that may be analysed only with scientifically compatible records.

Reported-result review

Qualitative, narrative, or review-first results interpreted in their source context.

Endpoints in scopeHalf Life

Evidence interpretation

Result type, analysis use, and source-check status are kept separate so a numerical value is not mistaken for a universally comparable result.

Eligible for matched-context analysis

Quantitative results whose endpoint and context must still be matched before analysis.

Interpret as reported

Qualitative, narrative, or review-first findings preserved in source context.

Supporting context only

Reference, label, clinical, or supporting context for interpretation.

Review before analysis

Records whose present structure does not establish a safe analysis role.

Evidence by endpoint

Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.

Half Life12 records · 12 matched-context · 0 as reported · 0 context only · 0 review required

#	Value	Analysis use	Assay / model	Result context	Reference
1	47 ± 1 Minutes 2820 seconds	Eligible when experimental context matches	RP-HPLC · Tris HCl buffer with 0.156 mM [Ala1]sialorphin inhibitor	Result: Reported point value · Molecular form: ATLPF0029076 · Dose/window: 0.0413 mM · NEP (5.687 Nm) · In Vitro · Source: Primary reference linked	Reference
2	74 ± 2 Minutes 4440 seconds	Eligible when experimental context matches	RP-HPLC · Tris HCl buffer with 0.156 mM [Ala2]sialorphin inhibitor	Result: Reported point value · Molecular form: ATLPF0029076 · Dose/window: 0.0413 mM · NEP (5.687 Nm) · In Vitro · Source: Primary reference linked	Reference
3	109 ± 8 Minutes 6540 seconds	Eligible when experimental context matches	RP-HPLC · Tris HCl buffer with 0.156 mM [Ala3]sialorphin inhibitor	Result: Reported point value · Molecular form: ATLPF0029076 · Dose/window: 0.0413 mM · NEP (5.687 Nm) · In Vitro · Source: Primary reference linked	Reference
4	52 ± 2 Minutes 3120 seconds	Eligible when experimental context matches	RP-HPLC · Tris HCl buffer with 0.156 mM [Ala5]sialorphin inhibitor	Result: Reported point value · Molecular form: ATLPF0029076 · Dose/window: 0.0413 mM · NEP (5.687 Nm) · In Vitro · Source: Primary reference linked	Reference
5	114 ± 2 Minutes 6840 seconds	Eligible when experimental context matches	RP-HPLC · Tris HCl buffer with 0.156 mM [Arg2]sialorphin inhibitor	Result: Reported point value · Molecular form: ATLPF0029076 · Dose/window: 0.0413 mM · NEP (5.687 Nm) · In Vitro · Source: Primary reference linked	Reference
6	116 ± 1 Minutes 6960 seconds	Eligible when experimental context matches	RP-HPLC · Tris HCl buffer with 0.156 mM [His2]opiorphin inhibitor	Result: Reported point value · Molecular form: ATLPF0029076 · Dose/window: 0.0413 mM · NEP (5.687 Nm) · In Vitro · Source: Primary reference linked	Reference
7	139 ± 3 Minutes 8340 seconds	Eligible when experimental context matches	RP-HPLC · Tris HCl buffer with 0.156 mM [Pro4]opiorphin inhibitor	Result: Reported point value · Molecular form: ATLPF0029076 · Dose/window: 0.0413 mM · NEP (5.687 Nm) · In Vitro · Source: Primary reference linked	Reference
8	53 ± 1 Minutes 3180 seconds	Eligible when experimental context matches	RP-HPLC · Tris HCl buffer with 0.156 mM [Ser4]sialorphin inhibitor	Result: Reported point value · Molecular form: ATLPF0029076 · Dose/window: 0.0413 mM · NEP (5.687 Nm) · In Vitro · Source: Primary reference linked	Reference
9	94 ± 2 Minutes 5640 seconds	Eligible when experimental context matches	RP-HPLC · Tris HCl buffer with 0.156 mM Opiorphin inhibitor	Result: Reported point value · Molecular form: ATLPF0029076 · Dose/window: 0.0413 mM · NEP (5.687 Nm) · In Vitro · Source: Primary reference linked	Reference
10	78 ± 2 Minutes 4680 seconds	Eligible when experimental context matches	RP-HPLC · Tris HCl buffer with 0.156 mM Sialorphin inhibitor	Result: Reported point value · Molecular form: ATLPF0029076 · Dose/window: 0.0413 mM · NEP (5.687 Nm) · In Vitro · Source: Primary reference linked	Reference

1–10 / 12

Identity & reference map

24 sources

Reference-level support for checking reported names, sequence notation, and peptide identity agreement.

Summary8 reference groups

Identity type: canonical sequence
Reported notation: 1
Reference groups: 8
Measurements: 24
ATL peptide ID: ATLPC0026740

Identity concordance

Exact reported notation

Reported sequence string matches the current peptide notation.

2 / 24

Parent-residue compatible

Reported notation differs, but resolves to the same parent-residue display.

0 / 24

Different notation

Reported notation does not resolve to the current display sequence.

0 / 24

Source sequence not captured

No source-specific sequence was captured for comparison; this is not interpreted as agreement or disagreement.

22 / 24

Reported sequence notation

Exact2 references

YGGFM

Current identity

YGGFM

Reported names

brainpeps_observation_v2_29_3_35_13c8eadcbebccd7797e4brainpeps_observation_v2_29_3_35_5476af0d4b4ef3f5dd81

Reference map8 reference groups

Reference map

Grouped by reference link, with endpoint scope and reported identity kept visible.

Reference	Supports	Reported identity	Records
Reference Open	Persistence Half Life	No reported alias	12 identity 12 evidence
Reference Open	Distribution Blood Brain Barrier Penetration	No reported alias	2 identity 2 evidence
Reference Open	Distribution Blood Brain Barrier Penetration	No reported alias	2 identity 2 evidence
Reference Open	Distribution Blood Brain Barrier Penetration	No reported alias	2 identity 1 evidence
Reference Open	Distribution Blood Brain Barrier Penetration	brainpeps_observation_v2_29_3_35_5476af0d4b4ef3f5dd81 YGGFMexact	2 identity 1 evidence
Reference Open	Stability Serum Plasma Stability	No reported alias	1 identity 1 evidence
Reference Open	Identity only	brainpeps_observation_v2_29_3_35_13c8eadcbebccd7797e4 YGGFMexact	2 identity 0 evidence
Reference Open	Stability Serum Plasma Stability	No reported alias	1 identity 1 evidence

Data access & reproducibility

Stable record access, analysis-ready files, and scripted retrieval for reproducing this profile view.

Record scopePublic release

ATL peptide ID: ATLPC0026740
Identity type: canonical sequence
ADMET endpoints: 3
Evidence records: 24
Reference groups: 8
Release view: Public release

Data access

Structured peptide profile

JSON

Peptide-specific profile used by this page, including identity and evidence context.

Open JSON

Peptide catalogue

TSV

Complete frozen peptide table. Filter the ATL peptide ID column locally to isolate this record.

Download catalogue

Measurement catalogue

TSV

Complete frozen measurement table. Join or filter by ATL peptide ID for peptide-level analysis.

Download measurements

Programmatic access

The request returns the same structured peptide record used by this profile. The tabular downloads are complete frozen release tables and should be filtered locally by ATL peptide ID.

Open endpoint

GET /api/v1/peptides/ATLPC0026740

open

curl -sS 'https://admetatlas.scbdd.com/api/v1/peptides/ATLPC0026740' \
  -H 'accept: application/json' \
  -H 'X-Visibility: public_release'

Form

Topology

Modifications

Connections

Representations

Measurements

ATLPF0029076

—

Notation only

Link

Method

Confidence

Match

Open

Experimental coordinate entry

experimental

5 aa

Value

Analysis use

Assay / model

Result context

Reference

< 2 minutes

< 120 seconds

Eligible when experimental context matches

RP-HPLC · monkey · Rhesus monkey plasma

Result: Upper-bound measurement · Molecular form: ATLPF0029076 · Dose/window: 1-20mM · Time: Blood collected 5-60 minutes after peptide infused · Proteases from rhesus monkey plasma · in vitro · Source: Primary reference linked

Reference

12.8 minutes

768 seconds

Eligible when experimental context matches

TLC (Thin-layer chromatography) · human · Human plasma

Result: Reported point value · Molecular form: ATLPF0029076 · Dose/window: 300pg (pooled platelet-poor plasma) · Human plasma proteases · in vitro · Source: Primary reference linked

Reference

Value

Analysis use

Assay / model

Result context

Reference

47 ± 1 Minutes

2820 seconds

Eligible when experimental context matches

RP-HPLC · Tris HCl buffer with 0.156 mM [Ala1]sialorphin inhibitor

Result: Reported point value · Molecular form: ATLPF0029076 · Dose/window: 0.0413 mM · NEP (5.687 Nm) · In Vitro · Source: Primary reference linked

Reference

74 ± 2 Minutes

4440 seconds

Eligible when experimental context matches

RP-HPLC · Tris HCl buffer with 0.156 mM [Ala2]sialorphin inhibitor

Result: Reported point value · Molecular form: ATLPF0029076 · Dose/window: 0.0413 mM · NEP (5.687 Nm) · In Vitro · Source: Primary reference linked

Reference

109 ± 8 Minutes

6540 seconds

Eligible when experimental context matches

RP-HPLC · Tris HCl buffer with 0.156 mM [Ala3]sialorphin inhibitor

Result: Reported point value · Molecular form: ATLPF0029076 · Dose/window: 0.0413 mM · NEP (5.687 Nm) · In Vitro · Source: Primary reference linked

Reference

52 ± 2 Minutes

3120 seconds

Eligible when experimental context matches

RP-HPLC · Tris HCl buffer with 0.156 mM [Ala5]sialorphin inhibitor

Result: Reported point value · Molecular form: ATLPF0029076 · Dose/window: 0.0413 mM · NEP (5.687 Nm) · In Vitro · Source: Primary reference linked

Reference

114 ± 2 Minutes

6840 seconds

Eligible when experimental context matches

RP-HPLC · Tris HCl buffer with 0.156 mM [Arg2]sialorphin inhibitor

Result: Reported point value · Molecular form: ATLPF0029076 · Dose/window: 0.0413 mM · NEP (5.687 Nm) · In Vitro · Source: Primary reference linked

Reference

116 ± 1 Minutes

6960 seconds

Eligible when experimental context matches

RP-HPLC · Tris HCl buffer with 0.156 mM [His2]opiorphin inhibitor

Result: Reported point value · Molecular form: ATLPF0029076 · Dose/window: 0.0413 mM · NEP (5.687 Nm) · In Vitro · Source: Primary reference linked

Reference

139 ± 3 Minutes

8340 seconds

Eligible when experimental context matches

RP-HPLC · Tris HCl buffer with 0.156 mM [Pro4]opiorphin inhibitor

Result: Reported point value · Molecular form: ATLPF0029076 · Dose/window: 0.0413 mM · NEP (5.687 Nm) · In Vitro · Source: Primary reference linked

Reference

53 ± 1 Minutes

3180 seconds

Eligible when experimental context matches

RP-HPLC · Tris HCl buffer with 0.156 mM [Ser4]sialorphin inhibitor

Result: Reported point value · Molecular form: ATLPF0029076 · Dose/window: 0.0413 mM · NEP (5.687 Nm) · In Vitro · Source: Primary reference linked

Reference

94 ± 2 Minutes

5640 seconds

Eligible when experimental context matches

RP-HPLC · Tris HCl buffer with 0.156 mM Opiorphin inhibitor

Result: Reported point value · Molecular form: ATLPF0029076 · Dose/window: 0.0413 mM · NEP (5.687 Nm) · In Vitro · Source: Primary reference linked

Reference

78 ± 2 Minutes

4680 seconds

Eligible when experimental context matches

RP-HPLC · Tris HCl buffer with 0.156 mM Sialorphin inhibitor

Result: Reported point value · Molecular form: ATLPF0029076 · Dose/window: 0.0413 mM · NEP (5.687 Nm) · In Vitro · Source: Primary reference linked

Reference

Supports

Reported identity

Records

Reference

Open

Persistence

Half Life

No reported alias

12 identity

12 evidence

Reference

Open

Distribution

Blood Brain Barrier Penetration

No reported alias

2 identity

2 evidence

Reference

Open

Distribution

Blood Brain Barrier Penetration

No reported alias

2 identity

2 evidence

Reference

Open

Distribution

Blood Brain Barrier Penetration

No reported alias

2 identity

1 evidence

Reference

Open

Distribution

Blood Brain Barrier Penetration

brainpeps_observation_v2_29_3_35_5476af0d4b4ef3f5dd81

YGGFMexact

2 identity

1 evidence

Reference

Open

Stability

Serum Plasma Stability

No reported alias

1 identity

1 evidence

Reference

Open

Identity only

brainpeps_observation_v2_29_3_35_13c8eadcbebccd7797e4

YGGFMexact

2 identity

0 evidence

Reference

Open

Stability

Serum Plasma Stability

No reported alias

1 identity

1 evidence

ATLPC0026740

Sequence & molecular identity

Sequence & peptidoform

Structure & chemistry

Physicochemical profile

Computed developability descriptors

Distribution / Barrier

Metabolic & Proteolytic Stability

Excretion / Persistence

Evidence landscape

Product context

Identity & reference map

Data access & reproducibility

Structured peptide profile

Peptide catalogue

Measurement catalogue

ATLPC0026740

Sequence & molecular identity

Sequence & peptidoform

Structure & chemistry

Physicochemical profile

Computed developability descriptors

Distribution / Barrier

Metabolic & Proteolytic Stability

Excretion / Persistence

Evidence landscape

Product context

Identity & reference map

Data access & reproducibility

Structured peptide profile

Peptide catalogue

Measurement catalogue